Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44237   clinical trials with a EudraCT protocol, of which   7337   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-000179-36
    Sponsor's Protocol Code Number:MS200647_0054
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-08-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2021-000179-36
    A.3Full title of the trial
    An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies
    Estudio abierto, multicéntrico y de seguimiento para recopilar datos a largo plazo sobre participantes de varios estudios clínicos con bintrafusp alfa (M7824)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Bintrafusp alfa Program Rollover Study
    Estudio de continuación del programa Bintrafusp alfa
    A.3.2Name or abbreviated title of the trial where available
    Bintrafusp alfa Program Rollover Study
    Estudio de continuación del programa Bintrafusp alfa
    A.4.1Sponsor's protocol code numberMS200647_0054
    A.5.4Other Identifiers
    Name:IND numberNumber:124757
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMerck KGaA
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMerck KGaA
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMerck KGaA
    B.5.2Functional name of contact pointCommunication Center
    B.5.3 Address:
    B.5.3.1Street AddressFrankfurter Strasse 250
    B.5.3.2Town/ cityDarmstadt
    B.5.3.3Post code64293
    B.5.3.4CountryGermany
    B.5.4Telephone number+34900 810 844
    B.5.5Fax number+496151722000
    B.5.6E-mailservice@merckgroup.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameM7824
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNM7824
    D.3.9.2Current sponsor codeM7824
    D.3.9.3Other descriptive nameMSB0011359C / Bintrafusp alfa
    D.3.9.4EV Substance CodeSUB179957
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cervical cancer, and triple-negative breast cancer (TNBC)
    Cáncer de pulmón de células no pequeñas (NSCLC), cáncer de vías biliares (BTC), cáncer de cuello uterino y cáncer de mama triple negativo (TNBC)
    E.1.1.1Medical condition in easily understood language
    Non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), cervical cancer, and triple-negative breast cancer (TNBC)
    Cáncer de pulmón de células no pequeñas (NSCLC), cáncer de vías biliares (BTC), cáncer de cuello uterino y cáncer de mama triple negativo (TNBC)
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10073077
    E.1.2Term Intrahepatic cholangiocarcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10074879
    E.1.2Term Extrahepatic cholangiocarcinoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10017614
    E.1.2Term Gallbladder cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10008229
    E.1.2Term Cervical cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10075566
    E.1.2Term Triple negative breast cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate clinical safety of bintrafusp alfa in participants with solid tumors who continue treatment after completion of the primary/main analyses in parent bintrafusp alfa studies
    Evaluar la seguridad clínica de bintrafusp alfa en pacientes con tumores sólidos que continúan el tratamiento después de completar los análisis primarios / principales en los estudios originales de bintrafusp alfa.
    E.2.2Secondary objectives of the trial
    To evaluate clinical efficacy of bintrafusp alfa based on overall survival
    Evaluar la eficacia clínica de bintrafusp alfa en función de la supervivencia global
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Are ≥ 18 years of age at the time of signing the informed consent. In Japan, if a participant is at least 18 but < 20 years of age, written informed consent from his/her parent or guardian will be required in addition to the participant’s written consent.
    2. Are participants currently enrolled in an eligible bintrafusp alfa parent study, as indicated in the protocol, where the primary/main analysis has been completed or after discontinuation of study before primary/main analysis has been completed and who:
    • Are currently on active bintrafusp alfa treatment (alone as a monotherapy or following discontinuation of other combination treatment agents) in the parent study and without treatment interruption at the time of rollover study enrollment, OR.
    • Experienced a confirmed CR, PR, or SD in an eligible parent study, discontinued bintrafusp alfa treatment according to the parent study protocol, and subsequently developed disease progression and are willing to re-start bintrafusp alfa treatment deemed potentially beneficial by the participants’ physicians OR.
    • Discontinued from bintrafusp alfa treatment in an eligible parent study due to an AE(s) that was subsequently well controlled or completely resolved after stopping therapy, provided that the parent study protocol permits reinitiation of bintrafusp alfa if a participant discontinued treatment due to toxicity and these participants are willing to re-start bintrafusp alfa treatment deemed potentially beneficial by the participants’ physicians. Participants who have had AEs requiring permanent treatment discontinuation, like certain irAEs or certain bleeding events, as described in the protocol, are excluded from participation in this Rollover study.
    • Have completed End of treatment (EoT) assessment of a parent study.
    3. Male and Female participants must agree to use appropriate contraception and barriers, if applicable. For female participants of childbearing potential or for male participants who have female partners of childbearing potential, the following applies:
    Participants on active treatment must agree to continue to use highly effective contraception (i.e., methods with a failure rate of less than 1% per year; as described in the protocol) for both male and female participants if the risk of conception exists (Note: The effects of the study intervention on the developing human fetus are unknown as described in the protocol; thus, women of childbearing potential and men must agree to use highly effective contraception as stipulated in national or local guidelines). Highly effective contraception must be used 28 days prior to the first study intervention administration, for the duration of study intervention, and at least for 2 months (for female participants) or 4 months (for male participants) after stopping study intervention. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, the treating physician should be informed immediately.
    4. Capable of giving signed informed consent as indicated in the protocol and to comply with the requirements and restrictions listed in the ICF and this protocol.
    1. Tener ≥ 18 años en el momento de firmar el consentimiento informado. En Japón, si un participante tiene al menos 18 pero <20 años de edad, se requerirá el consentimiento informado por escrito de sus padres o tutores, además del consentimiento por escrito del participante.
    2. Son participantes actualmente inscritos en un estudio parental de bintrafusp alfa elegible, como se indica en el protocolo, donde se ha completado el análisis principal / primario o después de la interrupción del estudio antes de que se haya completado el análisis principal / primario y que:
    • Están actualmente en tratamiento activo con bintrafusp alfa (solo como monoterapia o después de la interrupción de otros agentes de tratamiento de combinación) en el estudio principal y sin interrupción del tratamiento en el momento de la inscripción en el estudio de continuación, O.
    • Experimentó una RC, RP o SD confirmada en un estudio principal elegible, interrumpió el tratamiento con bintrafusp alfa de acuerdo con el protocolo del estudio principal y, posteriormente, desarrolló una progresión de la enfermedad y está dispuesto a reiniciar el tratamiento con bintrafusp alfa que los médicos de los participantes consideran potencialmente beneficioso O.
    • Se interrumpió el tratamiento con bintrafusp alfa en un estudio principal elegible debido a un AA que posteriormente se controló bien o se resolvió por completo después de interrumpir el tratamiento, siempre que el protocolo del estudio principal permita la reiniciación de bintrafusp alfa si un participante interrumpió el tratamiento debido a toxicidad y estos participantes están dispuestos a reiniciar el tratamiento con bintrafusp alfa que los médicos de los participantes consideren potencialmente beneficiosos. Los participantes que hayan tenido EA que requieran la interrupción permanente del tratamiento, como ciertos EAI o ciertos eventos hemorrágicos, como se describe en el protocolo, están excluidos de la participación en este estudio Rollover.
    • Haber completado la evaluación de finalización del tratamiento (EoT) de un estudio principal.
    3. Los hombres y mujeres participantes deben aceptar utilizar métodos anticonceptivos y barreras adecuados, si corresponde. Para las mujeres participantes en edad fértil o para los hombres participantes que tienen parejas mujeres en edad fértil, se aplica lo siguiente:
    Los participantes en tratamiento activo deben aceptar continuar usando métodos anticonceptivos altamente efectivos (es decir, métodos con una tasa de fracaso de menos del 1% por año, como se describe en el protocolo) tanto para los hombres participantes como para las mujeres si existe el riesgo de concepción (Nota: Los efectos de la intervención del estudio en el feto humano en desarrollo se desconocen como se describe en el protocolo; por lo tanto, las mujeres en edad fértil y los hombres deben aceptar el uso de métodos anticonceptivos altamente efectivos según lo estipulado en las pautas nacionales o locales). Se debe utilizar un método anticonceptivo muy eficaz 28 días antes de la administración de la primera intervención del estudio, durante la duración de la intervención del estudio y al menos durante 2 meses (para las mujeres participantes) o 4 meses (para los hombres participantes) después de interrumpir la intervención del estudio. Si una mujer queda embarazada o sospecha que está embarazada mientras ella o su pareja participan en este estudio, se debe informar al médico de inmediato.
    4. Capacidad para otorgar el consentimiento informado firmado como se indica en el protocolo y de cumplir con los requisitos y restricciones enumerados en la ICF y este protocolo.
    E.4Principal exclusion criteria
    1. Pregnancy or currently in lactation.
    2. Known hypersensitivity to any of the study intervention ingredients.
    3. For participants reinitiating treatment with bintrafusp alfa at study entry: have received any systemic anticancer therapies/treatments since discontinuing bintrafusp alfa treatment.
    4. Concurrent treatment with prohibited drugs as indicated in the protocol.
    5. Participant has withdrawn consent from the parent study for any reason.
    6. Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study.
    1. Embarazo o período de lactancia.
    2. Hipersensibilidad conocida a cualquiera de los ingredientes de la intervención del estudio.
    3. Para los participantes que reiniciaron el tratamiento con bintrafusp alfa al ingresar al estudio: han recibido alguna terapia / tratamiento anticanceroso sistémico desde que interrumpieron el tratamiento con bintrafusp alfa.
    4. Tratamiento concurrente con fármacos prohibidos según lo indicado en el protocolo.
    5. El participante ha retirado el consentimiento del estudio parental por cualquier motivo.
    6. Cualquier otro motivo que, a juicio del Investigador, impida al paciente participar en el estudio.
    E.5 End points
    E.5.1Primary end point(s)
    Occurrence of AEs and treatment-related AEs
    Aparición de acontecimientos adversos y acontecimientos adversos relacionados con el tratamiento
    E.5.1.1Timepoint(s) of evaluation of this end point
    Starting from baseline in parent study
    A partir de la línea de base en el estudio parental
    E.5.2Secondary end point(s)
    Overall survival
    Sobrevivencia promedio
    E.5.2.1Timepoint(s) of evaluation of this end point
    Starting from baseline in parent study
    A partir de la línea de base en el estudio parental
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA8
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    China
    Japan
    Korea, Republic of
    Turkey
    Ukraine
    United States
    Belgium
    France
    Italy
    Spain
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is defined as the date of the last scheduled procedure shown in the SoA for the last participant in the study and when there are no other eligible parent studies ongoing from which participants could enroll in this rollover study.
    El final del estudio se define como la fecha del último procedimiento programado que se muestra en el SoA para el último participante en el estudio y cuando no hay otros estudios parentales elegibles en curso a partir de los cuales los participantes puedan inscribirse en este estudio de continuación.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 22
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 17
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 10
    F.4.2.2In the whole clinical trial 39
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After a participant has completed the study, has withdrawn consent, or has been withdrawn early, no further treatment is foreseen within the scope of this protocol. If required and in accordance with the study site’s SOC, symptom-guided appropriate treatment may be administered per the generally accepted medical practice and depending on the participant’s individual medical needs.
    On withdrawal from the study, participants may receive care they and their physicians agree upon.
    Después de que un participante haya completado el estudio, haya retirado el consentimiento o se haya retirado anticipadamente, no se prevé ningún tratamiento adicional dentro del alcance de este protocolo. Si es necesario y de acuerdo con el SOC del sitio del estudio, se puede administrar el tratamiento apropiado guiado por los síntomas según la práctica médica generalmente aceptada y dependiendo de las necesidades médicas individuales del participante.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-10-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-09-15
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA